CDK2 and breast cancer: In addition, BC-N102 exhibited dose-dependent downregulation of CDK2, CDK4, cyclin D1, and phosphorylated CDC35C while increasing the expression levels of cell cycle regulatory proteins (p21, p27, and p53, Figure 4D).